INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 45 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $778,000,000 | -20.4% | 1,000,000 | 0.0% | 0.01% | -31.2% |
| Q2 2017 | $978,000,000 | +4.4% | 1,000,000 | 0.0% | 0.02% | 0.0% |
| Q1 2017 | $937,000,000 | +4.6% | 1,000,000 | 0.0% | 0.02% | -5.9% |
| Q4 2016 | $896,000,000 | – | 1,000,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $56,098,000 | 1.12% |
| L & S Advisors Inc | 795,000 | $767,000 | 0.14% |
| OAKTREE CAPITAL MANAGEMENT LP | 9,964,000 | $9,690,000 | 0.11% |
| WEDBUSH SECURITIES INC | 13,000 | $1,251,000 | 0.07% |
| Kohlberg Kravis Roberts & Co. L.P. | 3,163,000 | $3,076,000 | 0.06% |
| ZAZOVE ASSOCIATES LLC | 246,000 | $240,000 | 0.02% |
| Balboa Wealth Partners | 21,000 | $20 | 0.01% |
| Russell Investments Group, Ltd. | 1,910,000 | $1,875,000 | 0.00% |
| GAMCO INVESTORS, INC. ET AL | 250,000 | $244,000 | 0.00% |
| Regal Investment Advisors LLC | 20,000 | $19,000 | 0.00% |